Posted by Michael Wonder on 18 Dec 2024
GSK’s B7-H3 targeted antibody drug conjugate, GSK’227, receives EMA Priority Medicines (PRIME) designation in relapsed extensive-stage small-cell lung cancer
16 December 2024 - Regulatory designation based on promising preliminary clinical data.
GSK announced today that the EMA has granted Priority Medicines (PRIME) Designation for GSK5764227, its B7-H3 targeted antibody drug conjugate being evaluated for the treatment of patients with relapsed extensive-stage small-cell lung cancer.
